Dancing Through Menopause Book Announced By Christian Author Betty Johansen
Christian author Betty Johansen has announced 'Dancing Through Menopause,' a faith-based book offering practical strategies for nutrition, exercise, and emotional well-being to help women navigate menopausal changes with confidence and spiritual growth.
Big Spring, United States, June 7, 2025 -- Wordsmith World announces the release of 'Dancing Through Menopause,' a new book by Christian author Betty Johansen that addresses physical, hormonal, and emotional aspects of menopause from a faith-based perspective. The book helps Christian women navigate this life transition with confidence and joy while maintaining their spiritual well-being.
For more information, visit https://bettyjohansen.com/dancing-through-menopause/
'Dancing Through Menopause' provides readers with an understanding of menopausal changes and offers practical strategies for managing symptoms. The book includes a self-assessment section that helps women analyze their unique menopausal experience, along with specific approaches to nutrition, intermittent fasting, and exercise that can alleviate common symptoms and improve overall health.
Betty Johansen draws from her background as a former educator, having taught Chemistry, Integrated Physics, and 7th Grade Science before retiring. A lifelong resident of West Texas, Johansen has transitioned from teaching to writing, creating Christian-inspired content that combines practical advice with spiritual guidance. Her scientific background gives her a unique perspective on explaining the biological processes of menopause while her faith informs the spiritual aspects of her approach.
'This book examines the science behind the physical, hormonal, and emotional aspects of menopause while offering ways to overcome its challenges,' said Johansen. 'My goal is to help women develop a healthier and more vibrant lifestyle during this significant transition. The Christian perspective provides an additional dimension of support that many women find valuable during this time.'
The book addresses common menopausal symptoms such as weight gain, hot flashes, and mood swings, presenting them as opportunities for personal growth and spiritual development. Johansen encourages readers to view menopause as a new phase in life that can be navigated with grace and faith. The book provides ways to approach these changes with a positive mindset while acknowledging the real challenges they present.
Unlike many health books that focus solely on physical symptoms, 'Dancing Through Menopause' takes a holistic approach that considers the whole person—body, mind, and spirit. This integrated method helps women not only manage their symptoms but also find meaning and purpose in this new stage of life.
Johansen's writing style makes complex medical information accessible to the average reader while providing depth for those seeking a more thorough understanding.
'Dancing Through Menopause' is now available through the author's website or through Amazon. For additional information about Betty Johansen and her other Christian-inspired works, visit https://bettyjohansen.com
Contact Info:
Name: Betty Johansen
Email: Send Email
Organization: Wordsmith World
Address: Texas, Big Spring, Texas 79720, United States
Website: https://bettyjohansen.com/
Release ID: 89161860
If there are any problems, discrepancies, or queries related to the content presented in this press release, we kindly ask that you notify us immediately at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or support you with press release takedowns. Ensuring accurate and trustworthy information is our unwavering commitment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
37 minutes ago
- Medscape
Population-Level Weight Loss Seen With Primary Care Protocol
CHICAGO — Encouraging patients to talk with their primary care physicians about weight management led to increased visits for obesity, population-wide weight loss, and increased revenue, researchers at the University of Colorado Anschutz School of Medicine (CU Anschutz) reported here at the American Diabetes Association (ADA) 85th Scientific Sessions. The researchers presented data from a 4-year study of the PATHWEIGH protocol, which was implemented at 56 primary care clinics across Colorado. Ultimately, 274,182 patients were part of the study, which has not yet been published. Although weight loss was low in the intervention group — 0.1 kg at 18 months — the intervention eliminated the typical expected weight gain population-wide. And indeed, that weight gain was about 0.1 kg in those who did not receive the intervention. "Our data is the first to scale an intervention to more than a quarter of a million people and prevent population weight gain," said Leigh Perreault, MD, associate professor of medicine in the division of endocrinology, metabolism and diabetes at CU Anschutz, who presented the data. Using a stepped-wedge cluster randomized trial design, researchers randomized clinics to offer usual care or the intervention. Each clinic eventually moved to using the intervention. Patients who received usual care would have visits during which weight could be discussed but clinicians did not have access to PATHWEIGH tools. Those who received the intervention had weight-specific visits and their doctors had access to the protocol. The Colorado group created PATHWEIGH to help primary care physicians fill the gap in obesity care in the face of growing numbers of overweight and obese Americans. Patients in the usual care or intervention group were alerted to the opportunity to have a weight-prioritized visit with their primary care physician. In the intervention group, patients were asked to complete a weight-management questionnaire before the visit, which the physician could then use as a prompt to talk with the patient during the visit. Researchers also provided clinicians with specialized support tools, education, and most importantly, a weight-specific template embedded in the electronic medical record. The template allowed for diagnosis, documentation of a weight-related discussion (for reimbursement), and orders for referrals, tests, and procedures, which streamlined workflow and made it easier to help patients, said Perreault. Physicians were asked to follow up with patients at least every 4 to 6 weeks. Use of the tools was optional, however. This meant that patients in the intervention group could get usual care with or without PATHWEIGH. At baseline, the mean age of patients was 54 years. About 53% were female, and 78% were non-Hispanic White, 11% Latino, 4% Black, and 2% Asian. Two thirds had commercial insurance and about a third were Medicare enrollees. Mean BMI was 31 kg/m2. At the end of the 4-year study, researchers found only about 25% of patients with a BMI of 25 kg/m2 or more received any discernible care for their weight, said Perreault. Discernible care might include adequate counseling about diet, exercise, and behavioral modification, referral to a dietitian or bariatric surgeon, or prescription of an anti-obesity medication. More people in the intervention group received such care. Those most likely to receive care had a BMI of at least 25 kg/m2, tended to be closer to age 50, were commercially insured, and were Latino or Black. However, said Perreault, an A1c in the prediabetes range, an estimated glomerular filtration rate in the stage 2 chronic kidney disease range, or the presence of a weight-related disease or complication did not prompt clinicians to offer help. Patients who did receive weight-related care during the intervention lost 2.37 kg more than those in the intervention group who received no care. Getting any sort of help with weight management made a difference, even outside the intervention. Those who received usual care offered weight management assistance lost 1.73 kg more than patients in the usual care group who received no care. Perreault said that providers spent no extra time on weight-prioritized visits and that using weight-related International Classification of Diseases 10 codes added more than $15 million to the health system's revenues over the 4-year study. PATHWEIGH outreach also resulted in "more than twice as many" visits for weight management, she said. 'Monumental' But Not 'Hugely Successful' "This is monumental work," said Ildiko Lingvay, MD, MPH, MSCS, a professor of internal medicine at University of Texas Southwestern Medical Center, Dallas, who chaired the session during which the study results were presented. Changing population weight by a pound is "like moving mountains," she said. However, added Lingvay, "It's not that I think this intervention was hugely successful." She's excited to see how the intervention works as it is adopted by others. Robert Kushner, MD, MS, a professor of medicine at Northwestern University Feinberg School of Medicine, Chicago, Illinois, offered the Colorado group "a big congratulations." "This is a really tough nut to crack," said Kushner, who was asked for comment. "There are significant barriers and challenges to treating obesity in primary care," he said. Many approaches basically remove the primary care physician from the equation by diverting patients to online platforms, coaching, or self-help, or weight-loss programs. "Embedding" the primary care physician is "the road less taken, to be honest," said Kushner, which PATHWEIGH successfully does. And it is an "innovative program for a healthcare system, population-level approach to the management of obesity." Looking ahead, the researchers should determine how to increase both clinician and patient engagement, said Kushner. It would also be useful to examine what triggers referrals to other services and to assess clinical outcomes and mediators of weight change, he said. Lastly, researchers should "determine the use and effectiveness of obesity medications. That's extremely important in the day we live," said Kushner. The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases. Perreault has disclosed receiving personal fees for speaking and/or consulting from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Ascendis, Medscape, WebMD, and UpToDate. Lingvay has reported consulting for AbbVie, Altimmune, Amgen, Alveus, Antag Therapeutics, AstraZeneca, Bayer, Betagenon, Bioio, Biomea, Boehringer Ingelheim, Carmot, Cytoki Pharma, Eli Lilly, Intercept, Janssen/J&J, Juvena, Keros Ther, Novo Nordisk, PharmaVentures, Pfizer, Regeneron, Roche, Sanofi, Shionogi, Source Bio, Structure Therapeutics, Target RWE, Terns Pharmaceuticals, The Comm Group, WebMD, and Zealand Pharma. Kushner has reported no conflicts related to PATHWEIGH but disclosed being a board member for Altimmune, Currax, Novo Nordisk, Structure Therapeutics, and Weight Watchers International, and a consultant for Eli Lilly and Regeneron.
Yahoo
an hour ago
- Yahoo
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for obesity and key comorbidities EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that it will present new preclinical data supporting apelin receptor (APJ) agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20–23, 2025, in Chicago, Illinois. 'Our preclinical data demonstrated that APJ activation can confer multiple benefits in models of diabetic obesity and heart failure, and enhance the effects of incretin therapy,' said Kristen Fortney, PhD, CEO and co‑founder of BioAge. 'We are advancing next‑generation APJ agonists to translate this promising biology into new therapies for obesity and its major comorbidities.' APJ is the receptor for apelin, an exercise-induced signaling molecule known as an exerkine. Apelin has been shown in preclinical studies to have the potential to recapitulate many of the downstream benefits of exercise. BioAge's discovery platform identified apelin signaling as a therapeutic target based on analysis of human aging cohorts, which revealed that higher levels of circulating apelin are predictive of improved physical function and increased longevity. BioAge has shown that in preclinical obesity models, APJ agonism can approximately double the weight loss induced by GLP-1 receptor agonists while restoring body composition and muscle function, suggesting that APJ agonists could serve as pharmacological exercise mimetics to enhance incretin therapy. BioAge is advancing multiple APJ agonist approaches, including both oral small-molecule and long-acting injectable formulations, with an IND filing targeted for 2026 [link]. In their two presentations, BioAge CMO and EVP Research Paul Rubin, MD, and scientist Shijun Yan, PhD, MBA, will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies. —Dr. Rubin's oral presentation will show that in mouse models of diabetic obesity, APJ agonist monotherapy reduced HbA1c to levels comparable to lean controls and improved glucose tolerance by 25%. When combined with an incretin, APJ agonism further improved glycemic control compared to the incretin alone. Currently, fewer than half of patients with type 2 diabetes achieve optimal glycemic control on current incretin therapies. — Dr. Yan's poster will show that in a mouse model of obesity-associated heart failure, APJ agonist monotherapy reduced cardiac hypertrophy and suppressed markers of cardiac injury. Combination of APJ agonism with an incretin provided enhanced cardioprotective benefits and greater weight loss compared to either treatment alone. Over half of heart failure patients have preserved ejection fraction, and approximately two-thirds of these patients have obesity. Current therapeutic options for obesity-associated HFpEF remain limited. Oral presentation: Saturday Jun 21, 2025 5:00 PM - 5:15 PM CDTTitle: An Oral Apelin Receptor Agonist Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with TirzepatideSession: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies—Take 1; W181 A-CPresenter: Paul Rubin, MD, Chief Medical Officer and EVP-Research Poster presentation: Sunday Jun 22, 2025 12:30 PM - 1:30 PM CDTTitle: The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection FractionSession: Poster Hall F1, Board No. 866Presenter: Shijun Yan, PhD, MBA, Senior Scientist, In Vivo Biology The visual materials for the presentations will be made available on the BioAge investor website concurrent with the beginning of their respective sessions. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. IND submission and initiation of a Phase 1 SAD/MAD trial are planned for mid-2025, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge's additional preclinical programs, which leverage insights from the Company's proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging. Forward-looking statements This press release contains 'forward-looking statements' within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, including BGE-102 and our APJ program, the timing and results of our planned clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, the timing of our IND filing for BGE-102 or our APJ program, our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates or their ultimate ability to treat human disease, the expected timeline for completing proteomic analysis, anticipated analytical results and the potential for identifying novel therapeutic targets, and general economic, industry and market conditions. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'possible,' 'will,' 'would,' and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to the imposition of tariffs and other trade barriers; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading 'Risk Factors' included in BioAge's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on May 6, 2025, and BioAge's other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or Chris Patil, media@ IR: Dov Goldstein, ir@ Partnering: partnering@ Web:
Yahoo
2 hours ago
- Yahoo
Mary Beth Nienhaus Activity Center officially opens, providing social opportunities for adults 50+
APPLETON, Wis. (WFRV) – After all of the anticipation and excitement, the Mary Beth Nienhaus Activity Center has finally opened, with a celebration event on Friday afternoon. The activity center, formerly known as the , provides adults 50 years and older with plenty of opportunities to socialize, learn and thrive. Green Bay native Tony Shalhoub to host global food docuseries on CNN From wellness studios to high-tech classrooms and gaming areas, the facility features a plethora of ways for adults looking to keep up their activity level to do so. It also features the only indoor pickleball court for adults in Appleton. The center is still holding a fundraiser, looking to raise about $6.5 million, and it is 85% of the way there. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
